menu
    • menu
    [{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Berotralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pint Pharma \/ BioCryst","highestDevelopmentStatusID":"12","companyTruncated":"Pint Pharma \/ BioCryst"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Berotralstat","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pint Pharma \/ Pint Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Pint Pharma \/ Pint Pharma"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pint Pharma \/ Pint Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Pint Pharma \/ Pint Pharma"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"OrphanDC","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"AUSTRIA","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pint Pharma \/ OrphanDC","highestDevelopmentStatusID":"12","companyTruncated":"Pint Pharma \/ OrphanDC"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Berotralstat","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pint Pharma \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Pint Pharma \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Berotralstat","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pint Pharma \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Pint Pharma \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Berotralstat","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Pint Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pint Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Pint Pharma

    Menu

    Pint Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pint Pharma

                            Austria arrow
                            PharmaVenue
                            Not Confirmed

                            Pint Pharma

                            Austria arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berotralstat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pint Pharma Approves ORLADEYO® for HAE Prevention in Peru

                            Details : Orladeyo (berotralstat), plasma kallikrein inhbitor, is the first oral therapy designed to prevent hereditary angioedema attacks in patients aged 12 and older.

                            Brand Name : Orladeyo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 09, 2024

                            Lead Product(s) : Berotralstat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pint Pharma

                            Austria arrow
                            PharmaVenue
                            Not Confirmed

                            Pint Pharma

                            Austria arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berotralstat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : BioCryst Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pint Pharma Approves ORLADEYO® (berotralstat) for HAE Prevention in Mexico for Ages 12+

                            Details : Orladeyo (berotralstat), an inhibitor of plasma kallikrein, is the first and only oral therapy specifically designed to prevent hereditary angioedema attacks in patients aged 12 and older.

                            Brand Name : Orladeyo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 13, 2024

                            Lead Product(s) : Berotralstat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : BioCryst Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pint Pharma

                            Austria arrow
                            PharmaVenue
                            Not Confirmed

                            Pint Pharma

                            Austria arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berotralstat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : BioCryst Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pint Pharma Approves ORLADEYO (berotralstat) for HAE Prevention in Brazil for Ages 12+

                            Details : Orladeyo (berotralstat), an inhibitor of plasma kallikrein, is the first and only oral therapy specifically designed to prevent hereditary angioedema attacks in patients aged 12 and older.

                            Brand Name : Orladeyo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 16, 2024

                            Lead Product(s) : Berotralstat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : BioCryst Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pint Pharma

                            Austria arrow
                            PharmaVenue
                            Not Confirmed

                            Pint Pharma

                            Austria arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegcetacoplan

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved

                            Sponsor : OrphanDC

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Empaveli is the First Treatment for PNH that Binds to the Complement Protein C3

                            Details : Empaveli (pegcetacoplan) is the first treatment for PNH that binds to the complement protein C3, which is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

                            Brand Name : Empaveli

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            October 17, 2023

                            Lead Product(s) : Pegcetacoplan

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved

                            Sponsor : OrphanDC

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pint Pharma

                            Austria arrow
                            PharmaVenue
                            Not Confirmed

                            Pint Pharma

                            Austria arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : PharmaEssentia

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi® (ropeginterferon alfa-2b-njft) in Latin...

                            Details : Under the agreement, Pint-Pharma will be obtaining and maintaining all marketing authorizations and commercializing BESREMi (ropeginterferon alfa-2b-njft), the first approved mono-pegylated proline interferon for polycythemia vera, a rare blood cancer, i...

                            Brand Name : Besremi

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 02, 2023

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : PharmaEssentia

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pint Pharma

                            Austria arrow
                            PharmaVenue
                            Not Confirmed

                            Pint Pharma

                            Austria arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berotralstat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : BioCryst Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioCryst Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile

                            Details : Orladeyo® (berotralstat) is the first and only oral therapy designed to prevent attacks of HAE in adult and pediatric patients 12 years and older. One capsule per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.

                            Brand Name : Orladeyo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 22, 2023

                            Lead Product(s) : Berotralstat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : BioCryst Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pint Pharma

                            Austria arrow
                            PharmaVenue
                            Not Confirmed

                            Pint Pharma

                            Austria arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berotralstat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : BioCryst Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO (berotralstat) in Latin America

                            Details : Under the terms of the agreement, Pint Pharma will be responsible for obtaining and maintaining all marketing authorizations and for commercializing ORLADEYO in the pan-LATAM region.

                            Brand Name : Orladeyo

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 09, 2022

                            Lead Product(s) : Berotralstat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : BioCryst Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth